GARDP’s pipeline  *(March 2021)*

<table>
<thead>
<tr>
<th>DISCOVERY</th>
<th>DISEASE AREA</th>
<th>TRANSLATIONAL</th>
<th>DEVELOPMENT</th>
<th>REGULATORY</th>
<th>IMPLEMENTATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMR Screening Consortium</td>
<td>SERIOUS BACTERIAL INFECTIONS</td>
<td>Pre-clinical / Early Clinical</td>
<td>Pediatric trials</td>
<td>Cefepime-tanibor-bactam (NCE)</td>
<td>Access strategy</td>
</tr>
<tr>
<td>Antibiotic potentiators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calibr / Scripps</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natural Products HIPS</td>
<td>Neonatal Sepsis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children’s Antibiotics</td>
<td>Paediatric Sepsis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sexually Transmitted Infections</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Potential candidate A**: (NCE or repurposed)
- **IV Fosfomycin**
- **Flomoxef**
- **Amikacin**
- **Polymyxin B**
- **Paediatric cefepime-tanibor-bactam (NCE) Venatorx Pharmaceuticals**

- **Potential candidate A**: (NCE or repurposed)
- **Treatment regimens**
- **Public health strategic efficacy and safety trials**

- **Regulatory paediatric plans**
- **(serious bacterial infections paediatric and neonates)**

- **Zoliflodacin (NCE)**
- **Entasis Therapeutics Inc.**

- **Approved in USA, with limited Neo & Paeds label**
- **Approved in EU, with Neo & Paeds label**
- **Approved in Asia: Neo & Paeds data**
- **Approved globally: Neo & Paeds data**
- **Approved in USA, with Neo & Paeds data**

- **Access strategy**
- **Including manufacturing development**
- **Surveillance / Prevalence studies**

* Development of cefepime-tanibor-bactam is sponsored by Venatorx Pharmaceuticals and has been funded in whole or in part with federal funds from NIAID/NIH/HHS and BARDA/ASPR/HHS in the United States and The Wellcome Trust in the United Kingdom